Interferon-alpha2b Chronic lymphocytic leukemia Early phase
Summary
Background: In prior pilot studies Interferon-alpha2b (IFN-alpha) was shown to be effective in B-cell type chronic lymphocytic leukemia (B-CLL). Therefore, the bene fit of an IFN-alpha-therapy in early phase B-CLL is assessed with respect to freedom from progression and long term survival in a randomized multicenter study. Material and methods: Patients with early phase B-CLL (Binet A) and high risk for progres sion (diffuse bone marrow infiltration plus serum level of thymidinkinase >5 U/l plus/or lymphocyte doubling time < 12 months) are randomized into an IFN-treatment group (arm A) or a watch and wait group (arm B). Patients who do not share the risk parameters are documented in another watch and wait arm C. Dosage of IFN-alpha is 3 χ 5 Mill. IE per week. Results: Out of 14 evaluable patients im arm A two patients achieved a complete remission (normalization of blood cell counts, no lymph nodes palpable) and three patients attained a partial remission. Three patients have stable disease, and one out of four patients with progressive disease was in need of chemotherapy. Ten out of 15 evaluable patients in arm Β have stable disease, but five others had progressive disease with four patients in need of chemotherapy. None of the 24 evaluable patients in arm C had progressive disease with need of chemo therapy. Conclusion: These preliminary results seem to prove the validity of the risk parameters and show the possible benefit of an IFN-treatment in early phase B-CLL at high risk for progression. 
Introduction
The majority of previously untreated patients with early phase B-cell chronic lymphocytic leukemia (B-CLL, stage Binet A) expects a long-lasting indolent course of the disease. Long time survival of these patients does not differ from that of an age and sex matched control population [1] . However, approxi mately 30% of the patients will have progressive disease within two years after establishment of diagnosis. Diffuse bone mar row infiltration [2], lymphocyte doubling time > 12 months [3] , and serum levels of thymidine kinase >5 U/l [4] have been iden tified as risk factors for progression. In pilot studies, interferon-alpha2b (IFN-cc) has been shown to be efficient for B-CLL [5, 6] . In Binet stage A disease a decrease of circulating malignant B-lymphocytes was achieved. In addition, IFN-cc treatment induced an increase in serum immunoglobulin levels [7] . The possible benefit of an IFN-oc treatment of Binet stage A B-CLL at high risk for progression is therefore being exam ined in an ongoing randomized multicenter study. The goals of the study are freedom from progression and from chemothera py, and overall survival. 
Material and Methods

Inclusion
Results
Two out of 14 evaluable patients of the IFN-treatment group achieved a complete remission defined as normalization of pe ripheral blood counts and absence of enlarged lymphnodes. Three patients attained a partial remission and three other pa tients had stable disease. In four patients progression occurred and one of them was in need of chemotherapy. Due to toxic side effects (fever, nausea, depression) the treatment was 
Discussion
These preliminary results seem to show the benefit of an IFN-α treatment of early stage B-CLL at high risk for progression. Antileucemic effects of IFN-α had been reported earlier in pi lot studies on B-CLL [5, 6, 7] . It has been shown, that IFN-α is more effective in early stage than in late stage disease [8] . In this still ongoing randomized trial the effectiveness of IFN-α appears to become evident. While four out of 14 patients treat ed with IFN-α had progressive disease, only one of them was in need of chemotherapy. In the high risk group, however, five out of 15 patients had progressive disease and four of them needed chemotherapy. Moreover, the randomization concept seems to be confirmed as none of the patients without risk factors were in fact in need of specific therapy. These preliminary data sup port the validity of the risk factors, i.e. diffuse bone marrow in filtration, short lymphocyte doubling time, and high levels of serum thymidine kinase. Whether IFN-α could decrease the use of chemotherapy and prolong overall survival requires a greater number of patients and follow-up investigation of this ongoing trial.
